The Food and Drug Administration (FDA) is alerting patients and healthcare professionals about counterfeit Ozempic (semaglutide) injection pens that have been found in the legitimate U.S. drug supply chain. The FDA has seized several hundred units of the counterfeit product.
The agency is advising patients to only obtain Ozempic prescriptions from licensed pharmacies and to carefully inspect the product. Key indicators of the counterfeit pens include a different appearance and labeling inconsistencies. The FDA is investigating the matter and working to remove the fake Ozempic from circulation.
Ozempic is an FDA-approved prescription medicine used to lower blood sugar in adults with type 2 diabetes, along with diet and exercise. It is also approved to reduce the risk of major cardiovascular events such as stroke, heart attack, or death in adults with type 2 diabetes with known heart disease. Using counterfeit medication can pose a serious risk to patients, as the product may contain incorrect ingredients, be contaminated, or lack the active ingredient needed for treatment. Patients who suspect they have received a counterfeit Ozempic pen should contact the FDA and their healthcare provider immediately.
FDA Warns of Counterfeit Ozempic Found in US Supply Chain
The U.S. Food and Drug Administration (FDA) has issued a warning about counterfeit Ozempic pens discovered within the U.S. drug supply. The agency seized hundreds of fake units and is urging patients and healthcare providers to verify the authenticity of their medication. Patients using Ozempic should obtain the medicine from a trusted source and carefully inspect the product before use. This advisory aims to protect individuals from potentially harmful or ineffective treatments.
Source: Read the original article at NBC